a n a ly s i s Several genetic alterations characteristic of leukemia and lymphoma have been detected in the blood of individuals without apparent hematological malignancies. The Cancer Genome Atlas (TCGA) provides a unique resource for comprehensive discovery of mutations and genes in blood that may contribute to the clonal expansion of hematopoietic stem/progenitor cells. Here, we analyzed blood-derived sequence data from 2,728 individuals from TCGA and discovered 77 blood-specific mutations in cancer-associated genes, the majority being associated with advanced age. Remarkably, 83% of these mutations were from 19 leukemia and/or lymphoma-associated genes, and nine were recurrently mutated (DNMT3A, TET2, JAK2, ASXL1, TP53, GNAS, PPM1D, BCORL1 and SF3B1). We identified 14 additional mutations in a very small fraction of blood cells, possibly representing the earliest stages of clonal expansion in hematopoietic stem cells. Comparison of these findings to mutations in hematological malignancies identified several recurrently mutated genes that may be disease initiators. Our analyses show that the blood cells of more than 2% of individuals (5-6% of people older than 70 years) contain mutations that may represent premalignant events that cause clonal hematopoietic expansion.
Blood cells are continuously regenerated by hematopoietic stem/progenitor cells (HSPCs). Human HSPCs divide only rarely (estimated at once a month) but have self-renewal properties that sustain survival for decades. As HSPCs divide, they accumulate rare random mutations that generally do not affect function 1 . However, some mutations confer advantages in self-renewal, proliferation or both, resulting in clonal expansion of the affected cells. Although these 'initiating' mutations do not lead directly to disease, they can cooperate with subsequent mutations to cause hematopoietic malignancies. For example, BCR-ABL and BCL2 oncogenic translocations have been found in blood cells of individuals without overt hematological malignancies [2] [3] [4] . The frequency of such events appears to increase with age, with a similar trend being found for somatic structural changes in the nuclear genomes of blood cells 1, 5 . Single nucleotide polymorphism array analysis from large genome-wide association study cohorts showed ~2-3% of normal individuals of advanced age (70s and 80s) harbor leukemia-associated copy number changes that include genes such as DNMT3A (encoding DNA (cytosine-5-)-methyltransferase 3α) and TET2 (encoding tet methylcytosine dioxygenase 2) 6, 7 . More recently, somatic recurrent TET2 mutations were detected in the blood of elderly women without overt hematological malignancies 8 , and DNMT3A mutations were reported in nonleukemic cells 9 .
These findings have collectively led to the hypothesis that certain genetic mutations may confer advantages to affected HSPCs, resulting in enhanced cell renewal, clonal expansion or both. However, it is unclear whether the effect involves only a small number of genes or many more genes related to leukemia and lymphoma and whether their participation in promoting clonal expansion necessarily leads to clones resembling cancer cells. Here, we address the former question by analyzing variations in 2,728 blood samples in The Cancer Genome Atlas (TCGA). We observed many individuals with age-related hematopoietic clonal mosaicism and concurrent presence of over 60 mutations in 19 leukemia-and/or lymphoma-associated genes. Our study identified not only genes but also specific mutations, associated with the clonal expansion process. Additional statistical analysis identified low-level (2-10% variant allele fractions (VAFs)) recurrent leukemic mutations in a substantial number of cases, possibly in the early stages of clonal expansion. Moreover, our analysis suggests that DNMT3A, TET2, JAK2 (encoding Janus kinase 2), ASXL1 (encoding additional sex combs-like transcriptional regulator 1), SF3B1 (encoding splicing factor 3b, subunit 1) and TP53 (encoding tumor protein p53) have distinct and overlapping roles in the development of myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL) and/or acute myelogenous leukemia (AML). Finally, these results also incidentally highlight the need for caution when using blood as a reference for a surrogate 'germline' genome, especially in older individuals.
RESULTS

Sample characteristics and variant detection
We searched for variants present in the blood normal controls across 2,728 patients with cancer (Supplementary Table 1 ) from 11 diverse cancer types: breast adenocarcinoma (BRCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), brain low-grade glioma (LGG), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian carcinoma (OV), prostate adenocarcinoma (PRAD), stomach adenocarcinoma (STAD) and uterine corpus endometrioid carcinoma (UCEC). The numbers of cases from each tumor type ranged from 57 (KIRC) to 673 (BRCA) and are listed in Supplementary Table 2 . Patients were diagnosed between 10 and 90 years of age (mean 59.5 ± 13.1 years (s.d.)), and 22.1% were deceased at the time of TCGA sample procurement (Supplementary Table 2 ). TCGA collects clinical data regarding diagnosis and prior treatment of neoplasms during the sample submission process. To ensure that our data set comprised only individuals having first-time primary cancers and having had no treatment with radiation and/or chemotherapy, we excluded those having reported histories of these events based on TCGA Data Coordinating Center annotations and patient clinical data accessed 30 July 2014. However, five patients with synchronous tumors not associated with blood were included because these synchronous tumors would be unlikely to affect variant analysis in corresponding blood samples.
We identified variants in the 2,728 blood normal controls with VarScan (single nucleotide variant and indel), Genome Analysis Toolkit (GATK; single nucleotide variant and indel) and Pindel (indel) (Online Methods). False-positive filters were subsequently applied before downstream analysis and interpretation (Online Methods). Out of the 49,317,027 variants (previously reported OV counts 10 were not included here) that passed false-positive filters, 1,622,485 with minor allele frequency of <1% in the 1000 Genomes reference and in each cancer cohort were retained for further analysis; these consist of 1,025,632 missense, 529,505 synonymous, 19,663 nonsense, 10,976 splice site, 926 nonstop/readthrough, 20,275 frameshift indel and 15,508 in-frame indel mutations (Supplementary Table 3 ). We used a stringent filtering strategy described previously 11 for standardizing specificity of somatic mutation detection across available matched tumor samples (Supplementary Table 4 ).
Variants associated with hematopoietic clonal expansion
The collection of both tumor and matched blood normal exome data by TCGA provides a unique comparative resource for identifying those somatic variants in blood that are associated with clonal expansion. We set out to identify both rare truncation variants (RTVs), that is, those having <1% minor allele frequency (MAF) in both the 1000 Genomes collection and the cohort data, and variants overlapping with recurrent somatic mutations (also called known hotspot variants (KHVs)) found in the analysis of 12 TCGA cancer types (see Online Methods and Supplementary Tables 5 and 6). Subsequently, we manually reviewed 1,598 RTVs in 556 cancer-associated genes based on several recent studies [11] [12] [13] [14] [15] (see Online Methods and Supplementary Table 7) to remove false-positive calls and identified 136 KHVs in the same set of cancer genes. We further filtered the resulting list to remove polymorphisms npg a n a ly s i s present in 1000 Genomes (see Online Methods) and having greater than 0.1% MAF as reported in the current Exome Variant Server data release (ESP6500SI-V2, http://evs.gs.washington.edu/EVS/) from 6,503 samples drawn from multiple NHLBI Exome Sequencing Project (ESP) cohorts. We focused on those mutations found in blood normal samples but not present or present only at very low levels in either the tumor samples or tumor-adjacent normal samples, as this pattern is highly suggestive of somatic mutation in HSPCs introduced by the clonal expansion process. Inflammatory lymphocytes, macrophages and neutrophils will infiltrate different tumors to different extents. Therefore, the hematopoietic mutations do not have to be completely absent in the tumor sample. Our analysis of RTVs and KHVs in 556 selected cancer-associated genes identified 70 blood-specific mutations in 58 individuals. We further performed comparative analysis of blood versus tumor samples for these 58 individuals with the goal of detecting all blood-specific nonsynonymous mutations in the 556 cancer-associated genes; this analysis identified seven additional events (those that were probably loss of heterozygosity related to copy number alterations in the tumor were not included), yielding a final list of 77 blood-specific mutations in 58 cases ( Table 1 and Supplementary Table 8 ). For 5 of those 58 cases that also had adjacent normal tissue analyzed, blood variants were absent in the adjacent normal tissue. Notably, among the 31 genes harboring these events, 19 have already been linked to hematological malignancies (Fig. 1a) . In fact, 64 out of the total 77 events (83%) were in these 19 Fig. 1a ). The overall frequency of blood-specific mutations increased with age (logistic regression analysis, P = 2.38 × 10 −8 ); for example, 0.9% of the cases were in their 40s, 1.0% in their 50s, 1.8% in their 60s, 5.3% in their 70s and 6.1% in their 80s (Fig. 1b) . The blood-specific mutations were found in all 11 cancer types (Fig. 1b) . Frequencies of individual TET2, DNMT3A, ASXL1 and SF3B1 mutations also show association with age (all false discovery rate (FDR) values <0.034, logistic regression). TET2, ASXL1 and SF3B1 mutations were predominantly found in the oldest age groups (70s and 80s) and DNMT3A mutations in 60s to 80s. In contrast, JAK2 mutations, which did not achieve significance, trended in both younger (40s and 50s) and older age groups (70s) (Fig. 1c) .
The average age of the 54 individuals with blood-specific mutations in the 19 leukemia-and/or lymphoma-associated genes was 70.0 ± 9.9 years, significantly higher than that of the larger TCGA cohort used in this study (difference of means test, P = 3.4 × 10 −10 ) (Fig. 2a) . Notably, the 6 individuals having 2 blood-specific mutations in the 9 recurrently mutated genes are relatively older, with ages of 64 years (DNMT3A: R882H, 36% VAF; TET2: H863fs, 12% VAF), 72 years 
Samples with two mutations Age data missing Table 8 ). We also compared the distribution of VAFs for these 64 events versus inherited sites identified in the same sample set and observed a clear shift toward lower VAFs in the blood-specific sites (Fig. 2b) , suggesting the majority are present in only a fraction of the blood cells.
Although GNAS (encoding (guanine nucleotide binding protein, α stimulating) complex locus) mutations have been found in leukemia 26 , activating gain-of-function mutations in GNAS are best known for their involvement in polyostotic fibrous dysplasia and McCune-Albright syndrome 27 . Previous studies have shown that activating mosaic GNAS mutations could affect various tissue types and that the nonmosaic state for activating GNAS mutations may be lethal for embryos [28] [29] [30] . This is consistent with our finding of mosaic GNAS R202H in transcript ENST00000354359 (also known as R201H in transcript ENSP00000360126) in the three blood samples of TCGA cases (11.5%, 14.4% and 21.4% VAFs, respectively). It is also worth noting that we detected two blood-specific truncation mutations in PPM1D (encoding Mg 2+ /Mn 2+ -dependent protein phosphatase 1D), a gene recently found to be associated with breast and ovarian predisposition with mosaic signatures 31 , but not with hematological malignancies.
Given that the blood-specific variants were present in only a fraction of the blood cells, we postulated that certain low-level variants associated with clonal expansion were not captured by the variant detection tools. Therefore, we performed read count-based analysis for a set of known hotspot variants, including R882 in DNMT3A, R132 in IDH1 (encoding isocitrate dehydrogenase 1), R172 and/or R140 in IDH2, V617 in JAK2, K700 in SF3B1 and S34 in U2AF1 (encoding U2 small nuclear RNA auxiliary factor 1), for the entire TCGA cohort. We compared the distributions of VAFs between tumor and blood normal samples and found that the strongest differences were at R882 in DNMT3A and V617 in JAK2 (Fig. 3 and Table 1 ). We devised a statistical procedure (see Online Methods) to identify additional low-VAF sites significantly above the background error rate. Our analysis identified 14 blood samples having low-level hotspot variants (12 of them are not part of the 58 cases identified), including eight in DNMT3A, four in JAK2 and one in both SF3B1 and IDH2, but none in IDH1 or U2AF1. The average age for these 14 cases is 64.0 ± 14.9 years, again higher than the entire TCGA cohort studied (Supplementary Table 9 ). We performed deep sequencing for five selected low-level hotspot variants (one R882H and two R882C sample sites in DNMT3A, one V617F in JAK2 and one K700E in SF3B1) to evaluate our detection approach. We achieved more than 450,000-fold average coverage for each site, and all of the five variants were validated as bona fide low-level blood specific mutations (Supplementary Table 10 and Online Methods). By including low-VAF events, the overall frequencies of blood-specific mutations in different age groups are 1.2%, 1.3%, 2.2%, 6.1% and 6.8% for subjects in their 40s, 50s, 60s, 70s and 80s, respectively (Supplementary Fig. 1) . Collectively, we estimate that approximately 2% and 3.5% of individuals over the ages of 40 and 60, respectively, and without overt hematological malignancies, carry blood-specific mutations that are associated with hematological malignancies.
Cancer mutations in NHLBI exome sequencing project control cohort To confirm that these mutations are also present in an independent set of normal blood samples, we examined the NHLBI ESP control cohort. We searched for RTVs and KHVs in 6,503 ESP samples, focusing on four AML-associated genes discovered in the TCGA set (DNMT3A, TET2, JAK2 and ASXL1). When we applied a 0.1% MAF threshold in ESP (to focus on rare variants and to prevent potential false positives), we identified eight RTVs and 13 KHVs in DNMT3A, 13 RTVs in TET2, seven RTVs in ASXL1 and three KHVs in JAK2 (Supplementary Table 11) .
For a subset of ESP samples (n = 557 Women's Health Initiative Exome Sequencing Project (WHISP)), we realigned reads and performed variant analysis using the same process applied for the TCGA cohort. This allowed us to confirm RTVs and KHVs detected by the pipeline and also to detect low-VAF KHVs potentially missed by variant detection tools. Our pipeline detected one RTV each in DNMT3A, TET2 and ASXL1, four DNMT3A R882H mutations and two JAK2 V617F mutations. Careful analysis of recurrent hotspot sites (described in the previous section) using the 557 WHISP samples identified an additional three DNMT3A R882, one JAK2 V617, one GNAS R202 and two SF3B1 K700 variants with VAFs ranging from 2% to 10% (Fig. 3 and Supplementary Table 12) . On the basis of npg a n a ly s i s these analyses, over 2% of the 557 WHISP cases contain mutations in these five selected genes. However, sequencing of matched nonblood samples from these cases would be required to prove that they are truly blood-specific mutations.
Comparison with mutations in patients with hematological malignancies
We next compared the mutation frequencies in 25 genes frequently mutated in at least one of the five following cohorts: 58 TCGA blood samples, 151 MPN cases reported by Nangalia et al. 32 , MDS cases reported by Walter et al. 33 , 160 CLL cases reported by Landau et al. 34 and 200 TCGA AML cases 21 . DNMT3A, TET2, ASXL1, TP53 and SF3B1 were consistently mutated in at least four groups, whereas JAK2 was more specifically mutated in 58 TCGA blood samples and in patients with MPN (Fig. 4a) . No mutations were found in TCGA blood samples in genes such as IDH1, NRAS (encoding neuroblastoma v-ras oncogene homolog), RUNX1 (encoding runt-related transcription factor 1) and PHF6 (encoding PHD finger protein 6), which are significantly mutated in AML and frequently mutated in MPN and/or MDS. Several genes showed cohort specificity: GNAS was mutated only in TCGA blood samples and CEBPA, WT1, PTPN11, KIT, SMC1A and SMC3 were preferably mutated in the AML cohort. We reasoned that common mutations among the cohorts (for example, in DNMT3A, TET2, ASXL1, SF3B1, JAK2 and TP53) may be relevant for initiating HSPC clonal expansion and are also likely to be early initiation events for hematological malignancies, such as MPN, MDS, CLL and AML. On the other hand, gene mutations specific for MPN, MDS, and/or AML (for example, in NRAS, RUNX1, NPM1 (encoding nucleophosmin) and FLT3 (encoding fms-related tyrosine kinase 3)) are more likely to be subsequent cooperating mutations that are involved in the progression of these diseases. These observations also show both distinct and common connections among these five cohort groups, suggesting that the TCGA cohort consists of a combination of precursor mutations that may sometimes evolve to MPN, MDS, CLL and/or AML, although subsequent collaborating mutations are clearly required (Supplementary Fig. 2) . Finally, we compared the average number of mutations among these four cohorts (not including MDS) in 556 selected cancer-associated genes; this showed TCGA blood samples having the fewest mutations, MPN and CLL cohorts having intermediate numbers of mutations and subjects with AML harboring the highest number of mutations (Fig. 4b) .
DISCUSSION
We identified age-related hematopoietic clonal expansion and the concurrent presence of leukemia-and/or lymphoma-associated mutations in about 2% of individuals studied, who did not have reported hematological malignancies; this frequency reaches 5-6% for individuals who are at least 70 years of age. Our investigations of 2,728 TCGA blood samples identified 64 mutations in 19 genes known for their roles in hematological malignancies with VAFs above 10%, and an additional 14 mutations with lower VAFs (2-10%) when site-specific analysis was conducted. Although many of these genes (for example, DNMT3A, JAK2, ASXL1 and TET2) are established drivers for hematological malignancies, others (for example, PPM1D) have not yet been implicated. The wide range of VAFs is indicative of the different stages of clonal expansion among individuals. Our finding also supports the hypothesis that mutations in genes such as DNMT3A, JAK2, ASXL1, TET2, GNAS and others are likely to be initiating events for MPN, MDS, CLL and/or AML, wherein epigenetic changes have also been previously implicated 35, 36 . Notably, the lack of detectable mutations in IDH1, RUNX1, NRAS, NPM1 and FLT3 in both TCGA blood samples and WHISP cases supports the idea that these mutations are usually cooperating mutations that are important for disease progression.
These data suggest that extra care is required when using blood as a surrogate reference for the germline genome, especially in elderly individuals. First, there is an obvious risk of blood-specific variants in individuals without overt hematological malignancy being mistaken as germline variants. Second, germline alleles in cancer samples could be mistaken as tumor-specific variants when comparing to blood samples. Lastly, connections were made between mosaic PPM1D mutations in lymphocytes and the predisposition to breast and ovarian cancers 31 . Although the influence of the immune system on tumorigenesis is well known, it is also possible that the bloodspecific mutations are independent, unrelated events that are simply associated with the clonal expansion of HSPCs. Our unbiased mutational analysis using sequencing data of relatively high depth (average of 107.5× coverage, Supplementary Table 13 ) allowed us to detect hotspot mutations down to 2-3% VAFs; we discovered that 5-6% cases with advanced age (over 70 years) carry blood-specific mutations known to be involved in hematological malignancies. Some of these individuals may be undergoing hematopoietic clonal expansion (Fig. 5) , but most probably do not progress to overt disease, as the incidence of myeloid malignancies in the elderly is less than 0.1% (ref. 37) . Participants providing specimens to TCGA are de-identified and de-coded, so it is not feasible to determine whether a participant with a leukemia-associated mutation actually progressed to a malignant hematologic disease (Supplementary Fig. 2 ). Using single nucleotide polymorphism array data from GENEVA study cohorts (melanoma, lung health, prostate cancer, etc.), Laurie et al. 7 showed that roughly 2-3% of elderly individuals (over 70 years) have chromosomal anomalies in blood samples. We therefore suggest that our estimate of frequency may be conservative, as other types of alterations (such as gene fusions and copy number alterations) were not included in our study. Regardless, these data clearly show that the elderly often acquire clonal skewing in their hematopoietic compartments and that this may represent a contributing factor to the development of hematologic malignancies.
METHODS
Methods and any associated references are available in the online version of the paper. 
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Background mutation Figure 5 Clonal expansion model. Proposed roles of a set of genes including DNMT3A, ASXL1, TET2, GNAS, JAK2, PPM1D, IDH1, NRAS, NPM1 and FLT3 in the initiation of hematopoietic clonal expansion. Proposed early initiation mutations are in green circles and proposed subsequent cooperating mutations are in red triangles. The genes were ordered on the basis of their mutation frequencies in this study as well as in ref. 21 . 'Background mutation' refers to mutations that arise stochastically in a genome, which are random and do not have roles in disease. 
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ONLINE METHODS
We analyzed the peripheral blood sequence data from 2,728 individuals having had first-time primary cancer and no radiation or chemotherapy treatment. Exome data were aligned to human reference build 37 using BWA 38 , and variants were identified using VarScan 39 , GATK 40 and Pindel 41 , with stringent downstream filtering to standardize specificity. Variant annotation was based on Ensembl release 70_37_v5. The list of 556 cancer-associated genes was compiled from publicly available screening panels, published studies and preliminary analysis of publicly available data sources [11] [12] [13] [14] [15] 42 . Read count analysis was performed with our bam-readcount tool, available at https://github.com/genome/bam-readcount. Low-level blood-specific events were discovered using a two-stage process including pre-filtering candidate non-mosaic samples using Bayes's rule and then the detection of high probability mosaic sites using Fisher's exact test.
Variant calling and annotation strategies. Exome sequencing data were aligned to NCBI Build 37 of the human reference using BWA v0.5.9 and deduplicated using Picard 1. . For Pindel analysis, we preset the insertion size to 500 if this information was not provided in the BAM header. SNVs were based on the union of GATK and VarScan. They were subsequently processed through our in-house false-positive filter (−min-homopolymer 10). We required that indels were called by at least 2 out of 3 callers (GATK, Varscan, Pindel). In addition we also included Pindel unique calls (at least 30× coverage and 20% VAF). All combined indels were then processed through our false-positive-filter (-min-homopolymer 10 −min-var-freq 0.2 −min-var-count 6). We then applied additional annotation and minor allele frequency filters as previously reported 10 . Variant transcript annotation is based on all human transcripts obtained from Ensembl Release 70_37_v5. The reference alleles and positions were derived from the sequence and coordinates of GRCh37. All transcripts were annotated, and a single representative was selected for each somatic mutation based on the significance of the predicted functional effect of each mutation, ordered from most significant to least significant as follows: nonsense, frameshift, splice site, in frame, missense, no stop (nonstop/readthrough), synonymous and RNA. Splice site mutations were restricted to substitutions, deletions or insertions overlapping the 2-bp intronic sequence defined as the canonical splice donor or splice acceptor. RNA mutations were restricted solely to transcripts without an annotated open reading frame. Mutations affecting 3′ UTR, 5′ UTR, intronic sequence and intergenic sequence were discarded for the purposes of downstream analysis.
Recurrent somatic mutations in 12 cancer types. We collected extensively filtered somatic variants in 3,355 TCGA samples from 12 cancer types (Supplementary Table 5 ) and selected recurrent mutations appearing more than once at a given genomic position (Supplementary Table 6 ).
Compiling cancer-associated gene list. A total of 556 candidate cancerassociated genes was compiled using nine sources, including recently published large-scale cancer studies, publicly available screening panels and unpublished preliminary analysis of publicly available data sources. The 204 genes shared across at least two of the nine sources were retained, and a literature search was conducted to identify evidence supporting inclusion of any remaining unique genes. A subset of 518 genes originated from recent publications, including 294 genes from Frampton et al. 15 , 125 genes from Kandoth et al. 11 , 212 genes from Lawrence et al. 13 , 194 genes from Pritchard et al. 14 Table 7 ).
Read count analysis and statistical approaches for identifying significant low-level variants. Read counts for variants were determined using our internally developed tool bam-readcount. For sites to be included in the downstream statistical test, we require greater than 30× coverage for both blood normal and matched tumor samples. We assessed the false-discovery rate (FDR) using a two-stage process. The first step is a purpose-specific prefilter to eliminate candidates that can be confidently identified as having originated from nonmosaic samples, as these identically fail the inclusion criterion for significance testing. It targets deeply covered sites whose apparent variant reads actually represent base-calling errors. Take the sample space for blood classification as consisting of two mutually exclusive, collectively exhaustive (MECE) statuses, 'normal' , S = N, and 'mosaic' , S = M, and let the candidate blood site data, D, consist of T spanning reads, of which V and T-V report variant and reference counts, respectively. If we presume that the rate of mosaicism (the fraction of altered cells, assumed as roughly 2%), ρ, is much larger than the Phred-determined likelihood of base-calling error for any single read, ε, i.e., ρ/ε>>1, then the conditional probabilities are binomial, Candidates are culled as nonmosaic if this probability exceeds 95%, though in practice most cases actually removed have P(N|D)>99.5%. The remaining set of events is subsequently passed to the second step, which is a traditional Fisher's exact (table) test for association between sample type and variant allele fraction followed by standard Benjamini-Hochberg FDR assessment. We report events having ≤20% FDR with at least three supporting reads and greater than 2% variant allele fraction.
Analysis of NHLBI ESP data. NHLBI variants calls for 6,503 samples were downloaded from the NHLBI Exome Variant Server (http://evs.gs.washington. edu/EVS/). All variants were processed using the same tools as for the TCGA cohort. For comparative analysis, all ESP variants are filtered for <0.1% total MAF to minimize false positives. The Women's Health Initiative Exome Sequencing Project (WHISP) is part of the National Heart, Lung, and Blood Institute (NHLBI) Grand Opportunity Exome Sequencing Project (https://www. fhcrc.org/en/labs/phs/projects/cancer-prevention/projects/whisp.html). WHISP data for 614 samples were downloaded from dbGaP, verified for file integrity and then imported as BAM files into our data warehouse. Alignment to the reference genome GRCh37-lite was carried out using BWA v0.5.9 with parameters −t 4 −q 5 and marking of duplicates by Picard v1.46. Variant calling was performed as described above. For quality control purposes, we included WHISP samples with read mapping rates greater than 80%, duplication rates less than 40% and at least 10,000 SNVs detected in the target region. The 557 Caucasian WHISP samples selected for this study, on average, had mapping rates of ~95%, duplication rates of ~9% and ~18,000 SNVs called in the target region.
Deep sequencing validation.
Five candidate low-level variants (two R882C and one R882H sample sites in DNMT3A, one V617F in JAK2 and one K700E in SF3B1), 5 positive controls and 4 negative controls were selected for validation using deep sequencing (Supplementary Table 10 ). Primer pairs tailed with sample-specific indexes were designed for individual target sites and fsurther used for PCR amplifications. Indexed libraries were made for tumor and blood pools. We then generated sequencing data using 1 lane of MiSeq run with read length of 2 × 250. Custom references were created by including specific primer and index sequences. MiSeq reads were aligned to the custom references using BWA (bwa aln −t 8; bwa sampe). Allelic counts for the variants were obtained using in house tool bam-readcount (bam-readcount −b 0 −q 30). 
